Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
Launched by UNIVERSITY OF OKLAHOMA · Jun 26, 2023
Trial Information
Current as of September 07, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether a treatment called low-level vagus nerve stimulation can help improve heart health in people with breast cancer or lymphoma who have recently received certain types of chemotherapy. The researchers want to see if this treatment can make the heart function better, improve heart rate variations, and reduce inflammation in the body, which can be a concern after chemotherapy.
To participate in this study, individuals must be over 50 years old and have been treated with specific chemotherapy drugs in the last 60 to 90 days. They should also have at least one additional health concern, such as a history of heart issues, diabetes, or obesity. If someone joins the trial, they can expect to undergo the vagus nerve treatment and have their heart health monitored. It's important to note that some people may not be eligible, especially those with certain heart conditions or severe liver or kidney disease. If you're interested in learning more or think you might qualify, talking to your healthcare provider could be a good next step.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients (\>18 years) who have received anthracycline-based therapy for breast cancer or lymphoma within the last 30 days
- * A least 1 of following additional criteria:
- • previous chest radiation
- • . Age\>50
- • type 2 diabetes mellitus
- • hypertension
- • current smoking
- • obesity (BMI ≥ 30)
- • previous myocardial infarction
- • established atherosclerotic heart disease or significant valve disease. chronic kidney disease
- Exclusion Criteria:
- • Atrial paced rhythm
- • History of seizure currently on treatment
- • History of vasovagal syncope
- • End stage liver or kidney disease
About University Of Oklahoma
The University of Oklahoma, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials and research initiatives. With a robust network of interdisciplinary experts and state-of-the-art facilities, the university fosters an environment that promotes scientific discovery and the development of new treatments. Its commitment to patient-centered research ensures that clinical trials not only adhere to the highest ethical standards but also aim to address pressing health challenges. By collaborating with various stakeholders, including industry partners and healthcare providers, the University of Oklahoma seeks to translate research findings into tangible benefits for communities, ultimately enhancing the quality of care and improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
Patients applied
Trial Officials
Tarun W. Dasari, MD, MPH
Principal Investigator
University of Oklahoma
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported